Nelivaptan

Nelivaptan
Clinical data
Other namesSSR-149415; SSR-149,415; SSR149415; NB-415; NB415; BH-200; BH200
Routes of
administration		Oral
Drug classVasopressin V1B receptor antagonist
ATC code
  • None
Identifiers
  • (2S,4R)-1-[(3R)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxo-indolin-3-yl]-4-hydroxy-N,N-dimethyl-pyrrolidine-2-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.210.987 Edit this at Wikidata
Chemical and physical data
FormulaC30H32ClN3O8S
Molar mass630.11 g·mol−1
  • InChI=1S/C30H32ClN3O8S/c1-32(2)28(36)24-15-19(35)17-33(24)30(21-8-6-7-9-25(21)41-4)22-14-18(31)10-12-23(22)34(29(30)37)43(38,39)27-13-11-20(40-3)16-26(27)42-5/h6-14,16,19,24,35H,15,17H2,1-5H3/t19-,24+,30+/m1/s1 checkY
  • Key:NJXZWIIMWNEOGJ-WEWKHQNJSA-N checkY
 X markNcheckY (what is this?)  (verify)

Nelivaptan (INNTooltip International Nonproprietary Name; developmental code names SSR-149415, NB-415, and BH-200) is a selective, orally active, non-peptide vasopressin V1B receptor antagonist. The drug had entered clinical trials for treatment of anxiety and depression. In July 2008, Sanofi-Aventis announced that further development of this drug had been halted. Subsequently, nelivaptan was developed by Nelivabon for treatment of depressive disorders under the code name NB-145, but development was discontinued in 2022. However, it is also under development by HMNC Brain Health for major depressive disorder under the code name BH-200, and is in phase 2 trials for this indication as of August 2025.

See also

References

  1. 1 2 3 4 "Nelivaptan (SSR 149415)". AdisInsight. 2 October 2021. Retrieved 6 June 2026.
  2. 1 2 3 "NB 415". AdisInsight. 27 July 2022. Retrieved 6 June 2026.
  3. 1 2 3 "Nelivaptan (BH-200)". AdisInsight. 13 August 2025. Retrieved 6 June 2026.
  4. ↑ World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98" (PDF). WHO Drug Information. 21 (4): 341.
  5. ↑ Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002). "Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders". Proc. Natl. Acad. Sci. U.S.A. 99 (9): 6370–5. Bibcode:2002PNAS...99.6370G. doi:10.1073/pnas.092012099. PMC 122955. PMID 11959912.
  6. ↑ Serradeil-Le Gal C, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A (2005). "An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders". CNS Drug Reviews. 11 (1): 53–68. doi:10.1111/j.1527-3458.2005.tb00035.x. PMC 6741711. PMID 15867952.
  7. ↑ "Second-quarter 2008 results" (PDF). Press Release. Sanofi-Aventis. 2008-07-31. Archived from the original (PDF) on 2008-12-06. Retrieved 2009-06-10. It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist).
  8. ↑ "Delving into the Latest Updates on NB-415 with Synapse". Synapse. 7 May 2025. Retrieved 6 June 2026.
  9. ↑ kgi-admin (26 December 2024), Nelivaptan by HMNC for Major Depressive Disorder: Likelihood of Approval, retrieved 6 June 2026, Nelivaptan (NB-415, SSR-149415) is under development for the treatment of depression including major depressive disorder (MDD). The drug candidate targets vasopressin receptor 1B ((V1bR). It is administered through oral route in the form of capsule. It is being developed based on artificial intelligence platform.